# Application Value of Serum TK1 and PCDGF, CYFRA21-1, NSE, and CEA plus Enhanced CT Scan in the Diagnosis of Nonsmall Cell Lung Cancer and Chemotherapy Monitoring

Authors: Xiang He; Ming Wang
Journal: Journal of Oncology
 (2022)

---

## Abstract

Objective. To assess the application value of serum thymidine kinase 1 (TK1) and PC cell-derived growth factor (PCDGF), cytokeratin 19 fragment 21-1 (CYFRA21-1), neuron-specific enolase (NSE), and carcinoembryonic antigen (CEA) plus enhanced CT scan in the diagnosis of nonsmall cell lung cancer (NSCLC) and chemotherapy monitoring. Methods. Between April 2019 and April 2021, 30 patients with NSCLC assessed for eligibility treated in our institution were included in the experimental group, and 30 healthy individuals screened out from physical examinations were recruited in the control group. The chemotherapy regimens included gemcitabine plus cisplatin, pemetrexed disodium plus cisplatin, and vinorelbine plus cisplatin. The application value of serum TK1, PCDGF, CYFRA21-1, NSE, CEA, and enhanced CT scan in the diagnosis and chemotherapy monitoring of NSCLC was analyzed. Results. Before treatment, the eligible patients had significantly higher serum levels of TK1, PCDGF, CYFRA21-1, NSE, and CEA than those of the healthy individuals included (P<0.05). Clinical efficacy was categorized into good and poor, and the good efficacy included complete response and partial response, with the poor efficacy including stable disease and progressive disease. Patients with good clinical efficacy had lower levels of serum TK1, PCDGF, CYFRA21-1, NSE, and CEA than those with poor efficacy (P<0.05). Joint detection showed a larger area under the curve (AUC) (0.900; 95%CI, 0.812-0.988), a higher sensitivity, and a superior detection outcome to the stand-alone detection (P<0.05). Diagnostic results were similar between joint detection and pathological examination (P>0.05). Conclusion. The application of serum TK1, PCDGF, CYFRA21-1, NSE, and CEA assay plus enhanced CT scan shows high sensitivity and diagnostic accuracy in the diagnosis and chemotherapy monitoring of nonsmall cell lung cancer and thus provides a diagnostic reference basis.


---

## Body

## 1. Introduction

Lung cancer is a common malignant tumor, with high morbidity and mortality rates, posing a serious threat to patient's health and life safety [1]. According to statistics [2], the morbidity and mortality rates of lung cancer in men occupy the first place among all malignancies, and in women, the morbidity ranks third and the mortality ranks second. Clinical data show that nonsmall cell lung cancer (NSCLC) is associated with approximately 85% of lung cancer, and many cases have progressed to the advanced stage at the time of diagnosis due to the insidious symptoms and missed diagnosis. The 5-year survival of NSCLC is merely 11%-15% [3]. Thus, an urgent need exists to achieve effective early diagnosis and treatment of NSCLC patients. Diagnostic indices used clinically for NSCLC include cytokeratin fragment 19 antigen 21-1 (CYFRA21-1), neuron-specific enolase (NSE), and carcinoembryonic antigen (CEA), which, however, were found from relevant studies with modest sensitivity and specificity to meet clinical needs [4]. Given the insufficiency of single tumor marker assays in the diagnosis of lung cancer, combination with other detection methods is entailed to enhance the diagnostic accuracy [5, 6]. Thymidine kinase 1 (TK1), an enzyme that catalyzes the phosphorylation of thymidine to generate thymidine monophosphate, is strongly associated with DNA synthesis and cell proliferation and has demonstrated high diagnostic value in the NSCLC [7, 8]. PC cell-derived growth factor (PCDGF), a member of the growth regulator family, promotes tumorigenesis and development by binding to receptors and is expressed abnormally among lung cancer patients in particular [9, 10]. With the improvement of medical technology, CT scans are considered highly valuable in tumor diagnosis, but for a robust diagnostic accuracy, the combination of relevant tumor markers is also desired. Accordingly, this study was conducted to assess the application value of serum TK1, PCDGF, CYFRA21-1, NSE, and CEA plus enhanced CT scan in the diagnosis of NSCLC and chemotherapy monitoring.


## 2. Materials and Methods

### 2.1. Participants and Grouping

From April 2019 to April 2021, 30 eligible patients with NSCLC treated in our institution were recruited as the experimental group, and 30 healthy individuals screened out from physical examinations were included in the control group. The clinical baseline features of the eligible patients (19 males and 11 females, aged between 48 and 76 years, mean age of (54.35±5.61) years, 9 cases in TNM stage I-II and 21 cases in stage III-IV, 12 cases of squamous cell carcinoma, 6 cases of adenocarcinoma, 8 cases of small cell carcinoma, and 4 cases of large cell carcinoma) were comparable with those of the healthy individuals (18 males and 12 females, aged between 46-75 years, mean age of (55.29±6.34)) (P>0.05).


### 2.2. Inclusion and Exclusion Criteria

Inclusion criteria: (1) all patients who were diagnosed with NSCLC confirmed by imaging and histopathology; (2) with no chemotherapy, radiotherapy, or surgery before randomization; (3) the study was approved by the hospital ethics committee, and patients and family members had provided written informed consent.Exclusion criteria: (1) patients with serious heart, liver, kidney, and other functional abnormalities; (2) with other serious infectious diseases; (3) with other malignant tumors; (4) with mental illness.


### 2.3. Methods

#### 2.3.1. Chemotherapy

The eligible patients were all primary cases.Gemcitabine (Manufacturer: Qilu Pharmaceutical (Hainan) Co., Ltd.; State Drug Quantifier: H20113286; Specification: 1.0 g) plus cisplatin (Manufacturer: Yunnan Botanical Pharmaceutical Co., Ltd.; State Drug Registration: H53021740; Specification: 2 ml: 10 mg) regimen: gemcitabine 1250 mg/m2, d1-8 and cisplatin 75 mg/m2, used in 2 d. Pemetrexed disodium (Manufacturer: Qilu Pharmaceutical Co., Ltd.; State Pharmacopoeia: H20060672; specification: 0.2 g) plus cisplatin regimen: pemetrexed disodium 500 mg/m2, and cisplatin 75 mg/m2, used in 2 d. Vinorelbine (Manufacturer: Jiangsu Hengrui Pharmaceutical Co., Ltd.; State Drug Quantifier: H20061234; specification: 20 mg) plus cisplatin: vinorelbine 25 mg/m2, d1-8, cisplatin 75 mg/m2, used in 2 d. One treatment cycle consists of 21 d. Serum tumor markers determination and systemic assessment were performed after every 2 cycles of chemotherapy.


#### 2.3.2. Sample Collection

After fasting more than 10 h, 5 ml of morning venous blood was collected from all participants and centrifuged at a radius of 15 cm and 2500 r/min for 10 min to obtain the serum which was then stored at -20°C.


#### 2.3.3. Measurement of Serum Markers

Serum TK1, PCDGF determination: the serum TK1 level was determined by immunoradiometric analysis, and serum PCDGF level was determined by ELISA using double-antibody sandwich enzyme-linked immunosorbent assay. Serum CYFRA21-1, NSE, CEA determination: the CEA level was determined using the immunoradiometric assay, the CYFRA21-1 level was determined using the immunoradiometric assay, and the NSE level was determined using electrochemiluminescence. All assays were performed per the standards of the kit instructions.


#### 2.3.4. Enhanced CT Scan

A Siemens 64-row spiral CT machine was used to perform the contrast-enhanced CT scan, with the scanning conditions of 180 mA and 120 kv, a scanning area from the entrance of the thorax to the diaphragm plane, a layer thickness of 5 mm, and a scanning scope of 8 cm. The contrast agent was iohexol, 80-100 ml, and was administered through intravenous bolus injection at a rate of 3 ml/s using a high-pressure syringe. Multiphase scans were performed at 10 s, 15 s, 25 s, 50 s, 65 s, 120 s, 160 s, and 200 s after the injection.


### 2.4. Outcome

(1) Comparison of serum TK1, PCDGF, CYFRA21-1, NSE, and CEA levels before treatment between the two groups; (2) clinical efficacy of patients in the experimental group after chemotherapy. Clinical efficacy was evaluated as per RECIST criteria [11]: complete response (CR): all lesions disappeared, no new lesions appeared, tumor markers returned to normal and the above conditions were maintained for at least 4 weeks. Partial response (PR): the sum of the longest diameter of the tumor was reduced by ≥30% or more, and the above condition was maintained for at least 4 weeks. Stable disease (SD): the sum of the longest tumor diameters decreased by less than 30% or increased by less than 20%. Progressive disease (PD): the sum of the longest diameter of the tumor increased by ≥20% or new lesions appeared. Clinical efficacy was categorized into good and poor, and the good efficacy included complete response and partial response, with the poor efficacy including stable disease and progressive disease. (3) Comparison of serum TK1, PCDGF, CYFRA21-1, NSE, and CEA levels after treatment between the two groups. (4) Analysis of the correlation between posttreatment serum TK1, PCDGF, CYFRA21-1, NSE, and CEA levels in the eligible patients and the efficacy. (5) Analysis of the diagnostic value of serum TK1, PCDGF, CYFRA21-1, NSE, CEA levels, enhanced CT scan, and joint detection.


### 2.5. Statistical Analysis

SPSS20.0 was used for data analyses, and GraphPad Prism 7 (GraphPad Software, San Diego, USA) was used to visualize the data into matching images. Count data were expressed as (n%) and were subject to the chi-square test. The measurement data were expressed as (x¯±s) and processed using the t-test. Differences were considered statistically significant when P<0.05.


## 2.1. Participants and Grouping

From April 2019 to April 2021, 30 eligible patients with NSCLC treated in our institution were recruited as the experimental group, and 30 healthy individuals screened out from physical examinations were included in the control group. The clinical baseline features of the eligible patients (19 males and 11 females, aged between 48 and 76 years, mean age of (54.35±5.61) years, 9 cases in TNM stage I-II and 21 cases in stage III-IV, 12 cases of squamous cell carcinoma, 6 cases of adenocarcinoma, 8 cases of small cell carcinoma, and 4 cases of large cell carcinoma) were comparable with those of the healthy individuals (18 males and 12 females, aged between 46-75 years, mean age of (55.29±6.34)) (P>0.05).


## 2.2. Inclusion and Exclusion Criteria

Inclusion criteria: (1) all patients who were diagnosed with NSCLC confirmed by imaging and histopathology; (2) with no chemotherapy, radiotherapy, or surgery before randomization; (3) the study was approved by the hospital ethics committee, and patients and family members had provided written informed consent.Exclusion criteria: (1) patients with serious heart, liver, kidney, and other functional abnormalities; (2) with other serious infectious diseases; (3) with other malignant tumors; (4) with mental illness.


## 2.3. Methods

### 2.3.1. Chemotherapy

The eligible patients were all primary cases.Gemcitabine (Manufacturer: Qilu Pharmaceutical (Hainan) Co., Ltd.; State Drug Quantifier: H20113286; Specification: 1.0 g) plus cisplatin (Manufacturer: Yunnan Botanical Pharmaceutical Co., Ltd.; State Drug Registration: H53021740; Specification: 2 ml: 10 mg) regimen: gemcitabine 1250 mg/m2, d1-8 and cisplatin 75 mg/m2, used in 2 d. Pemetrexed disodium (Manufacturer: Qilu Pharmaceutical Co., Ltd.; State Pharmacopoeia: H20060672; specification: 0.2 g) plus cisplatin regimen: pemetrexed disodium 500 mg/m2, and cisplatin 75 mg/m2, used in 2 d. Vinorelbine (Manufacturer: Jiangsu Hengrui Pharmaceutical Co., Ltd.; State Drug Quantifier: H20061234; specification: 20 mg) plus cisplatin: vinorelbine 25 mg/m2, d1-8, cisplatin 75 mg/m2, used in 2 d. One treatment cycle consists of 21 d. Serum tumor markers determination and systemic assessment were performed after every 2 cycles of chemotherapy.


### 2.3.2. Sample Collection

After fasting more than 10 h, 5 ml of morning venous blood was collected from all participants and centrifuged at a radius of 15 cm and 2500 r/min for 10 min to obtain the serum which was then stored at -20°C.


### 2.3.3. Measurement of Serum Markers

Serum TK1, PCDGF determination: the serum TK1 level was determined by immunoradiometric analysis, and serum PCDGF level was determined by ELISA using double-antibody sandwich enzyme-linked immunosorbent assay. Serum CYFRA21-1, NSE, CEA determination: the CEA level was determined using the immunoradiometric assay, the CYFRA21-1 level was determined using the immunoradiometric assay, and the NSE level was determined using electrochemiluminescence. All assays were performed per the standards of the kit instructions.


### 2.3.4. Enhanced CT Scan

A Siemens 64-row spiral CT machine was used to perform the contrast-enhanced CT scan, with the scanning conditions of 180 mA and 120 kv, a scanning area from the entrance of the thorax to the diaphragm plane, a layer thickness of 5 mm, and a scanning scope of 8 cm. The contrast agent was iohexol, 80-100 ml, and was administered through intravenous bolus injection at a rate of 3 ml/s using a high-pressure syringe. Multiphase scans were performed at 10 s, 15 s, 25 s, 50 s, 65 s, 120 s, 160 s, and 200 s after the injection.


## 2.3.1. Chemotherapy

The eligible patients were all primary cases.Gemcitabine (Manufacturer: Qilu Pharmaceutical (Hainan) Co., Ltd.; State Drug Quantifier: H20113286; Specification: 1.0 g) plus cisplatin (Manufacturer: Yunnan Botanical Pharmaceutical Co., Ltd.; State Drug Registration: H53021740; Specification: 2 ml: 10 mg) regimen: gemcitabine 1250 mg/m2, d1-8 and cisplatin 75 mg/m2, used in 2 d. Pemetrexed disodium (Manufacturer: Qilu Pharmaceutical Co., Ltd.; State Pharmacopoeia: H20060672; specification: 0.2 g) plus cisplatin regimen: pemetrexed disodium 500 mg/m2, and cisplatin 75 mg/m2, used in 2 d. Vinorelbine (Manufacturer: Jiangsu Hengrui Pharmaceutical Co., Ltd.; State Drug Quantifier: H20061234; specification: 20 mg) plus cisplatin: vinorelbine 25 mg/m2, d1-8, cisplatin 75 mg/m2, used in 2 d. One treatment cycle consists of 21 d. Serum tumor markers determination and systemic assessment were performed after every 2 cycles of chemotherapy.


## 2.3.2. Sample Collection

After fasting more than 10 h, 5 ml of morning venous blood was collected from all participants and centrifuged at a radius of 15 cm and 2500 r/min for 10 min to obtain the serum which was then stored at -20°C.


## 2.3.3. Measurement of Serum Markers

Serum TK1, PCDGF determination: the serum TK1 level was determined by immunoradiometric analysis, and serum PCDGF level was determined by ELISA using double-antibody sandwich enzyme-linked immunosorbent assay. Serum CYFRA21-1, NSE, CEA determination: the CEA level was determined using the immunoradiometric assay, the CYFRA21-1 level was determined using the immunoradiometric assay, and the NSE level was determined using electrochemiluminescence. All assays were performed per the standards of the kit instructions.


## 2.3.4. Enhanced CT Scan

A Siemens 64-row spiral CT machine was used to perform the contrast-enhanced CT scan, with the scanning conditions of 180 mA and 120 kv, a scanning area from the entrance of the thorax to the diaphragm plane, a layer thickness of 5 mm, and a scanning scope of 8 cm. The contrast agent was iohexol, 80-100 ml, and was administered through intravenous bolus injection at a rate of 3 ml/s using a high-pressure syringe. Multiphase scans were performed at 10 s, 15 s, 25 s, 50 s, 65 s, 120 s, 160 s, and 200 s after the injection.


## 2.4. Outcome

(1) Comparison of serum TK1, PCDGF, CYFRA21-1, NSE, and CEA levels before treatment between the two groups; (2) clinical efficacy of patients in the experimental group after chemotherapy. Clinical efficacy was evaluated as per RECIST criteria [11]: complete response (CR): all lesions disappeared, no new lesions appeared, tumor markers returned to normal and the above conditions were maintained for at least 4 weeks. Partial response (PR): the sum of the longest diameter of the tumor was reduced by ≥30% or more, and the above condition was maintained for at least 4 weeks. Stable disease (SD): the sum of the longest tumor diameters decreased by less than 30% or increased by less than 20%. Progressive disease (PD): the sum of the longest diameter of the tumor increased by ≥20% or new lesions appeared. Clinical efficacy was categorized into good and poor, and the good efficacy included complete response and partial response, with the poor efficacy including stable disease and progressive disease. (3) Comparison of serum TK1, PCDGF, CYFRA21-1, NSE, and CEA levels after treatment between the two groups. (4) Analysis of the correlation between posttreatment serum TK1, PCDGF, CYFRA21-1, NSE, and CEA levels in the eligible patients and the efficacy. (5) Analysis of the diagnostic value of serum TK1, PCDGF, CYFRA21-1, NSE, CEA levels, enhanced CT scan, and joint detection.


## 2.5. Statistical Analysis

SPSS20.0 was used for data analyses, and GraphPad Prism 7 (GraphPad Software, San Diego, USA) was used to visualize the data into matching images. Count data were expressed as (n%) and were subject to the chi-square test. The measurement data were expressed as (x¯±s) and processed using the t-test. Differences were considered statistically significant when P<0.05.


## 3. Results

### 3.1. Serum TK1, PCDGF, CYFRA21-1, NSE, and CEA before Treatment

Before treatment, the serum levels of TK1, PCDGF, CYFRA21-1, NSE, and CEA of the eligible patients were higher than those of the healthy individuals included (P<0.05) (Table 1).Table 1
Comparison of serum TK1, PCDGF, CYFRA21-1, NSE, and CEA before treatment.
IndicesControl groupExperimental grouptPTK1 (pmol/L)0.72±0.317.49±1.5523.459<0.001PCDGF (ng/ml)9.11±0.5718.86±3.1916.480<0.001CYFRA21-1 (ng/ml)2.10±0.427.56±1.2422.843<0.001NSE (ng/ml)10.45±1.7819.63±7.286.709<0.001CEA (ng/ml)2.97±1.0329.47±7.3519.557<0.001


### 3.2. Clinical Efficacy

The CR, PR, SD, and PD of the eligible patients were 33.33%, 56.67%, 6.67%, and 3.33%, respectively (Figure1).Figure 1
Clinical efficacy of the eligible patients. Note: the abscissa indicates the clinical efficacy, and the ordinate indicates the percentage, %. Among the eligible patients, there were 10 cases of CR, 17 cases of PR, 2 cases of SD, and one case of PD.


### 3.3. Serum Levels of TK1, PCDGF, CYFRA21-1, NSE, and CEA in Patients with Different Clinical Efficacy

Eligible patients with good clinical efficacy showed lower levels of serum TK1, PCDGF, CYFRA21-1, NSE, and CEA versus those with poor efficacy (P<0.05) (Table 2).Table 2
Correlation of serum TK1, PCDGF, CYFRA21-1, NSE, and CEA with clinical efficacy.
IndicesGood efficacy (n=27)Poor efficacy (n=3)tPTK1 (pmol/L)1.47±0.645.39±1.209.266<0.001PCDGF (ng/ml)10.58±1.1617.41±3.038.131<0.001CYFRA21-1 (ng/ml)2.37±0.527.04±1.1313.116<0.001NSE (ng/ml)12.65±1.2916.51±2.054.669<0.001CEA (ng/ml)4.32±1.0610.34±3.667.099<0.001


### 3.4. AUC of Detection Approach

The joint detection using serum TK1, PCDGF, CYFRA21-1, NSE, CEA, and enhanced CT scan yielded a larger AUC versus stand-alone detection (Figure2).Figure 2
Comparison of AUC of single and joint detection.


### 3.5. Detection Outcomes

Joint detection of serum TK1, PCDGF, CYFRA21-1, NSE, and CEA, plus enhanced CT scan outperformed stand-alone detection using either the serum tumor markers or enhanced CT scan (P<0.05) (Table 3).Table 3
Comparison of detection outcomes.
95% confidence intervalVariablesAreaStandard erroraProgressive sig.BLower limitUpper limitTK10.6670.0710.0270.5280.806PCDGF0.6330.0720.0760.4910.775CYFRA21-10.7000.0690.0080.5650.835NSE0.7000.0690.0080.5650.835CEA0.7330.0660.0020.6030.864CT0.8170.0580.0000.7030.931TK1+PCDGF+CYFRA21-1+NSE+CEA0.8330.0560.0000.7240.943Joint detection0.9000.0450.0000.8120.988


### 3.6. Sensitivity and Specificity

A significantly higher sensitivity was obtained in the joint detection when compared with stand-alone detection (Table4).Table 4
Comparison of sensitivity and specificity between stand-alone detection and joint detection.
VariablesPositive if greater than or equal toaSensitivity1-SpecificityTK1-1.00001.0001.0000.50000.5330.2002.00000.0000.000PCDGF-1.00001.0001.0000.50000.4670.2002.00000.0000.000CYFRA21-1-1.00001.0001.0000.50000.6330.2332.00000.0000.000NSE1.00001.0001.0000.50000.6330.2332.00000.0000.000CEA1.00001.0001.0000.50000.6330.1332.00000.0000.000CT1.00001.0001.0000.50000.6000.1332.00000.0000.000TK1+PCDGF+CYFRA21-1+NSE+CEA1.00001.0001.0000.50000.7670.1332.00000.0000.000Joint detection1.00001.0001.0000.50000.8000.1002.00000.0000.000


### 3.7. Diagnostic Results

Diagnostic results were similar between joint detection and pathological examination (P>0.05) (Table 5).Table 5
Comparison of diagnostic results between joint detection and pathological examination.
Diagnostic resultsnDiagnosedMisdiagnosed and missed diagnosedDiagnostic ratesPathological examination3030 (100.00)0.00% (0/30)30 (100.00)Joint detection results3029 (96.67)1 (3.33)29 (96.67)x21.017P0.313


## 3.1. Serum TK1, PCDGF, CYFRA21-1, NSE, and CEA before Treatment

Before treatment, the serum levels of TK1, PCDGF, CYFRA21-1, NSE, and CEA of the eligible patients were higher than those of the healthy individuals included (P<0.05) (Table 1).Table 1
Comparison of serum TK1, PCDGF, CYFRA21-1, NSE, and CEA before treatment.
IndicesControl groupExperimental grouptPTK1 (pmol/L)0.72±0.317.49±1.5523.459<0.001PCDGF (ng/ml)9.11±0.5718.86±3.1916.480<0.001CYFRA21-1 (ng/ml)2.10±0.427.56±1.2422.843<0.001NSE (ng/ml)10.45±1.7819.63±7.286.709<0.001CEA (ng/ml)2.97±1.0329.47±7.3519.557<0.001


## 3.2. Clinical Efficacy

The CR, PR, SD, and PD of the eligible patients were 33.33%, 56.67%, 6.67%, and 3.33%, respectively (Figure1).Figure 1
Clinical efficacy of the eligible patients. Note: the abscissa indicates the clinical efficacy, and the ordinate indicates the percentage, %. Among the eligible patients, there were 10 cases of CR, 17 cases of PR, 2 cases of SD, and one case of PD.


## 3.3. Serum Levels of TK1, PCDGF, CYFRA21-1, NSE, and CEA in Patients with Different Clinical Efficacy

Eligible patients with good clinical efficacy showed lower levels of serum TK1, PCDGF, CYFRA21-1, NSE, and CEA versus those with poor efficacy (P<0.05) (Table 2).Table 2
Correlation of serum TK1, PCDGF, CYFRA21-1, NSE, and CEA with clinical efficacy.
IndicesGood efficacy (n=27)Poor efficacy (n=3)tPTK1 (pmol/L)1.47±0.645.39±1.209.266<0.001PCDGF (ng/ml)10.58±1.1617.41±3.038.131<0.001CYFRA21-1 (ng/ml)2.37±0.527.04±1.1313.116<0.001NSE (ng/ml)12.65±1.2916.51±2.054.669<0.001CEA (ng/ml)4.32±1.0610.34±3.667.099<0.001


## 3.4. AUC of Detection Approach

The joint detection using serum TK1, PCDGF, CYFRA21-1, NSE, CEA, and enhanced CT scan yielded a larger AUC versus stand-alone detection (Figure2).Figure 2
Comparison of AUC of single and joint detection.


## 3.5. Detection Outcomes

Joint detection of serum TK1, PCDGF, CYFRA21-1, NSE, and CEA, plus enhanced CT scan outperformed stand-alone detection using either the serum tumor markers or enhanced CT scan (P<0.05) (Table 3).Table 3
Comparison of detection outcomes.
95% confidence intervalVariablesAreaStandard erroraProgressive sig.BLower limitUpper limitTK10.6670.0710.0270.5280.806PCDGF0.6330.0720.0760.4910.775CYFRA21-10.7000.0690.0080.5650.835NSE0.7000.0690.0080.5650.835CEA0.7330.0660.0020.6030.864CT0.8170.0580.0000.7030.931TK1+PCDGF+CYFRA21-1+NSE+CEA0.8330.0560.0000.7240.943Joint detection0.9000.0450.0000.8120.988


## 3.6. Sensitivity and Specificity

A significantly higher sensitivity was obtained in the joint detection when compared with stand-alone detection (Table4).Table 4
Comparison of sensitivity and specificity between stand-alone detection and joint detection.
VariablesPositive if greater than or equal toaSensitivity1-SpecificityTK1-1.00001.0001.0000.50000.5330.2002.00000.0000.000PCDGF-1.00001.0001.0000.50000.4670.2002.00000.0000.000CYFRA21-1-1.00001.0001.0000.50000.6330.2332.00000.0000.000NSE1.00001.0001.0000.50000.6330.2332.00000.0000.000CEA1.00001.0001.0000.50000.6330.1332.00000.0000.000CT1.00001.0001.0000.50000.6000.1332.00000.0000.000TK1+PCDGF+CYFRA21-1+NSE+CEA1.00001.0001.0000.50000.7670.1332.00000.0000.000Joint detection1.00001.0001.0000.50000.8000.1002.00000.0000.000


## 3.7. Diagnostic Results

Diagnostic results were similar between joint detection and pathological examination (P>0.05) (Table 5).Table 5
Comparison of diagnostic results between joint detection and pathological examination.
Diagnostic resultsnDiagnosedMisdiagnosed and missed diagnosedDiagnostic ratesPathological examination3030 (100.00)0.00% (0/30)30 (100.00)Joint detection results3029 (96.67)1 (3.33)29 (96.67)x21.017P0.313


## 4. Discussion

Nonsmall cell lung cancer is a type of lung malignancy originating from the bronchial mucosa, bronchial glands, and alveolar epithelium and is classified into adenocarcinoma, squamous cell carcinoma, adenosquamous carcinoma, large cell carcinoma, and sarcomatoid subtypes as per histopathology [12]. The development of NSCLC is strongly associated with environmental factors and genes, such as age, genetics, immune and nutritional status, bad living habits, and environmental pollution. The insidiousness of early-stage symptoms usually results in an undesirable treatment timing [13, 14], which necessitates the significance of early diagnosis and treatment for NSCLC patients. Tumor markers are simple and noninvasive in the diagnosis of lung cancer, with great merit in the diagnosis of tumors, disease monitoring, and efficacy assessment [15]. Serum NSE is an acidic protease specific to neurons and neuroendocrine, a specific marker of neuroendocrine tumors [16, 17]. The origin of the NSCLC from neuroendocrine cells results in a key role of serum NSE in diagnosing NSCLC. CEA is an acidic glycoprotein with a human embryonic antigenic determinant cluster and a broad-spectrum tumor marker, which is widely used in differential diagnosis, disease monitoring, and efficacy determination of tumors [18]. CYFR21-1 is a filamentous substance that constitutes the cytoskeleton and is abundantly released during cell carcinogenesis to get involved in cell proliferation and metastasis [19]. Results of the present study showed lower levels of pretreatment CYFRA21-1, NSE, and CEA of the eligible patients versus healthy individuals, indicating that the diagnostic value of CYFRA21-1, NSE, and CEA in NSCLC. Research results by Wang et al. [20] revealed a mediocre sensitivity and specificity of the above three indices and proposed that joint detection may potentiate the diagnostic accuracy.Serum TK1 is a cell cycle-dependent marker that is closely related to cell proliferation as a kinase expressed in the cytoplasm [21]. It is a highly potent IA marker of cell proliferation with an essential role in systemic organ tumorigenesis and development, and its expression level indicates the degree of active cell proliferation [22]. PCDGF is involved in tumor cell adhesion, cell proliferation, angiogenesis, and extracellular matrix degradation through stimulation of mitogen-activated protein kinase signaling pathway, phosphatidylinositol 3-kinase signaling pathway, and local adhesion kinase signaling pathway to promote tumor cell infiltration and metastasis, where its high expression levels are associated with tumor development [23]. Here, the eligible patients showed significantly higher levels of TK1 and PCDGF versus healthy individuals (P<0.05), which was consistent with the research results by Chen et al. [24]. They revealed that the highly expressed TK1 and PCDGF levels were associated with the heavy release of TK1 from cancer tissue cells into the peripheral circulation and the regulatory role of PCDGF in tumor immunity. In the present study, patients with better clinical efficacy had lower serum levels of TK1, PCDGF, CYFRA21-1, NSE, and CEA versus those with poor clinical efficacy (P<0.05), indicating that the above indices demonstrate great potential in chemotherapy monitoring to provide a reference basis. CT scan is a major instrument for the diagnosis of NSCLC, which features excellent spatial and density resolution of lung tissues, improves the accuracy of target area contours, avoids missed imaging of target areas, and reduces radiation complications of normal tissues and organs, with high accuracy in the diagnosis of lung cancer. This study found that the sensitivity of the combined assay was significantly higher than that of the stand-alone detection, and there was no statistical difference (P>0.05) between the joint detection results and the pathological results, indicating a high diagnostic value of the combined assay.To sum up, the application of serum TK1, PCDGF, CYFRA21-1, NSE, and CEA assay plus enhanced CT scan shows high sensitivity and diagnostic accuracy in the diagnosis and chemotherapy monitoring of nonsmall cell lung cancer and thus provides a diagnostic reference basis.



---

*Source: 8800787-2022-03-25.xml*